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To examine whether serum levels of soluble interleukin-2 recep-
tor (sIL-2R) is a good marker of acute graft-versus-host disease
(aGVHD), they were measured in 37 patients receiving HLA-
haploidentical bone marrow transplantation (BMT). Grafts were
from HLA-haploidentical relatives. Conditioning regimen was
myeloablative including cyclophosphamide and toral body irradi-
ation. GVHD prophylaxis included tacrolimus (TAC)/solumedrol
(mPSL)/methotrexate (MTX) (n  11) and tacrolimus (TAC)/
solumedrol (mPSL)/methotrexate (MTX)/mycophenolate
mofetile (MMF) (n  27). Seventeen patients developed aGVHD
(Grade I, 9; Grade II, 5; Grade III, 3) after BMT. There was a
signiﬁcant correlation between occurrence of a GVHD and the
maximal serum level of sIL-2R. For 11 patients receiving GVHD
prophylaxis with TAC/mPSL/MTX, aGVHD occurred in 7 pa-
tients (63%). The mean maximal level of sIL-2R (SE) in 7
patients with a GVHD was 7086 (1066) and that in 4 patients
without aGVHD was 2770 (450). For patients with GVHD
prophylaxis with TAC/mPSL/MTX/MMF, aGVHD occurred in
10 patients (37%). The mean maximal level of sIL-2R in 10
patients with aGVHD was 3944 (655) and that in 17 patients
without aGVHD was 2566 (358). These data suggest that serum
levels of sIL-2R are useful for predicting the occurrence of
aGVHD after HLA-haploidentical BMT.
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Little is known regarding the immunopathogenesis of chronic
graft-versus-host disease (cGvHD) in children. From 2001
through 2005, the Children’s Oncology Group (COG) performed
a randomized, double blinded, placebo controlled phase three
study for newly diagnosed extensive cGvHD in children and ado-
lescents, ASCT0031. Based on murine model data and limited
human studies, we hypothesized that cGvHD would be character-
ized by a Th1/Tc1 shift in T cell activation. Correlative immuno-
logic studies were performed on patients at time of enrollment to
evaluate for immune cell populations and T cell function, including
cytokine production. Twenty-seven control patients without evi-
dence of cGvHD had peripheral blood collected at 3, 6, 9, and 12
months post hematopoietic stem cell transplant (HSCT) and were
used as time matched controls. Fifty-four patients with newly
diagnosed extensive cGvHD were evaluated and divided as early
cGvHD (3–5 months post HSCT; N  20) or late-onset cGvHD
(6 months post HSCT; N 34). Signiﬁcance was determined by
either a 50% increase or decrease of the mean value compared to
control with a P value  .05. In the early-onset cGvHD patients,
the total number of CD3, CD4, and CD8T cell subsets were
all lower relative to non-cGVHD controls, although none were
signiﬁcantly different. In the late onset cGVHD patients, a non-
statistically signiﬁcant increase in CD4 and CD8 T cell pop-
ulations were noted compared to time-matched controls. Func-
tional evaluations for cytokine production after in vitro PMA/
Ionomycin stimulation (intra-cytoplasmic staining by FACS)
revealed no signiﬁcant difference in either Th1 cytokine produc-
tion (IFN) by CD4 or CD8 T cells with early-onset (P  .82,
0.81, respectively) or late onset cGVHD (P  .40, P  .33,
respectively). Evaluation for a Th2/Tc2 shift revealed that IL-4 in
either CD4 or CD8 T cells at early-onset cGvHD (P  .35,
0.11, respectively) or late-onset cGvHD (P  .54, P  .64, respec-
tively) was not different. Thus, we were unable to demonstrate
either a Th1/Tc1 or Th2/Tc2 shift associated with newly diag-
nosed cGvHD in children. These results may be different to
previous adult HSCT studies in that there may be a difference in
the biology of chronic GvHD in younger HSCT recipients or that
these studies were limited to evaluation at the time of presentation
of disease.
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BRONCHIOLITIS OBLITERANS AND BRONCHIOLITIS OBLITERANS OR-
GANIZING PNEUMONIA IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANT: AN INSTITUTIONAL EXPERIENCE
Duncan, C.N., Buonanno, M.R., Callaway, G.D., Lehmann, L.E.
Dana-Farber Cancer Institute, Boston, MA.
Bronchiolitis obliterans (BO) and bronchiolitis obliterans orga-
nizing pneumonia (BOOP) are rare, well-recognized complications
of allogeneic stem cell transplant (SCT). Both BO and BOOP are
associated with high morbidity and mortality in adult patients.
However, in the pediatric population, the incidence and morbidity
of these complications have not been well described. We report
our institutional experience of BO and BOOP in 449 pediatric
allogeneic SCT patients between January 1, 1993 and December
31, 2004. The source of stem cells in this population was as follows:
200 unrelated donors, 198 siblings, 42 parents, 5 extended family
members, and 4 half-siblings. A total of 18 patients (4%) developed
BO (n  11) or BOOP (n  7) during this time. The diagnosis of
BO was based on pulmonary function test (PFT) abnormalities
(decline in FEV1 20% of baseline or FEV1/FVC 70%) or
characteristic histologic changes on lung biopsy. BOOP was diag-
nosed by pathology only. The most common conditioning regimen
was cyclophosphamide (Cy) and total body irradiation (TBI), used
in 12 patients. Cytarabine/Cy/TBI was used in 3 cases, Busul-
fan/Cy in 2, and 1 patient received Etoposide/Cy. All but 2 patients
received bone marrow as a stem cell source; the remaining patients
received peripheral blood stem cells. Three of the patients received
stem cells from fully matched related donors; 6 of the donors were
related, but matched at less than 6 of the 6 typed HLA loci. Nine
patients received fully matched unrelated donor transplants. The
median time to diagnosis of BO or BOOP was 329 days from stem
cell infusion. Ten patients had abnormal computed tomography
scans at diagnosis. Six patients were diagnosed by PFTs alone, 9 by
pathology alone, and 3 by PFTs and pathology. All patients were
treated with immunosuppression: 16 patients received corticoste-
roids, 15 patients received calcineurin inhibitors, and 2 patients
received mycophenolate mofetil. Azithromycin was used in 3 pa-
tients for anti-inﬂammatory effects. Four patients were treated
with other medication regimens. One patient (6%) experienced
complete resolution of pulmonary disease. Three patients (17%)
achieved partial resolution. Four patients (22%) had progressive
disease. Ten patients (56%) died; 7 of pulmonary disease and 3 of
unrelated causes. BO and BOOP, while uncommon, are associated
with considerable morbidity and mortality in pediatric SCT, and
new therapeutic modalities are needed to improve the outcome of
these patients.
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NEIC STEM CELL TRANSPLANTATION
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Parikh, S., Prasad, V., Kurtzberg, J. Duke University Medical Center,
Durham, NC.
Traditionally, pediatric patients are prophylaxed against acute
graft-versus-host disease (GvHD) with cyclosporine combined
with either methotrexate Mtx) or methylprednisolone (Pred). Mtx
worsens the severity of mucositis and renal insufﬁciency while pred
causes muscle wasting, hypertension and increased infections. Cell-
cept (myophenolic acid) is a better tolerated, less toxic agent with
synergistic immunosuppressive effects when combined with cyclo-
sporine or tacrolimus. We explored its use in combination with
cyclosporine in 21 pediatric patients undergoing allogeneic trans-
plantation. Patients with both malignant (n  7) and non-malig-
nant (n  14) conditions ranging in age from 2 weeks to 15 years
were transplanted after myeloablative preparative regimens with
either related bone marrow or cord blood (n 7) or unrelated cord
blood (n  14), using cellcept and cyclosporine for GVHD pro-
phylaxis. Cellcept and cyclosporine were administered intrave-
nously through the ﬁrst 40-60 days post transplant using cellcept at
a dose of 15mg/kg/dose IV q8H beginning on day -2 or -3. The
patient then transitioned to oral therapy at the same dose and
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